Skip to main content
GRML
NASDAQ Life Sciences

Greenland Mines Prices $20M Public Offering at $5.00/Share to Fund Sarfartoq Acquisition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$5.2
Mkt Cap
$16.711M
52W Low
$4.37
52W High
$38
52W Position info
19% above low
Off High info
86% below high
Rel. Volume info
6.4× avg
Market data snapshot near publication time

GRML sits 19% above its 52-week low of $4.37 on elevated volume (6.4× avg).

Summary

Greenland Mines priced a $20 million public offering at $5.00 per share, with net proceeds of ~$18.5 million to fund the Sarfartoq rare earth project acquisition and working capital.


Key Events · Financing and Capital Events · GRML

  • Offering Priced at $5.00/Share

    Greenland Mines priced a registered public offering of 1,632,783 shares plus pre-funded warrants for 2,367,517 shares at $5.00 per share (or $4.9999 per warrant), for aggregate gross proceeds of approximately $20 million.

  • Net Proceeds of ~$18.5M

    After placement agent fees (7.0% of gross proceeds) and offering expenses, net proceeds are expected to be approximately $18.5 million.

  • Use of Proceeds: Sarfartoq Acquisition

    Proceeds will fund the acquisition of the Sarfartoq Nd-Pr Rare Earth Element Project and provide working capital.

  • Closing Expected August 27, 2026

    The offering is expected to close on or about August 27, 2026, subject to customary closing conditions.


Analysis · GRML · Life Sciences

Greenland Mines has priced a registered public offering of 4 million shares (or equivalents) at $5.00 per share, raising approximately $18.5 million in net proceeds. The capital is earmarked for the Sarfartoq Nd-Pr rare earth project acquisition and working capital. This is a substantial capital raise for a company with a market cap of roughly $16.7 million and a going-concern warning from its most recent 10-Q. The offering provides critical runway to close the Sarfartoq acquisition, but it is highly dilutive to existing shareholders — the 4 million shares represent a significant expansion of the share count. The pricing at $5.00 is close to the current market price of $5.20, suggesting the deal was priced near market rather than at a deep discount, which is a modest positive signal for institutional demand.

How filings like this one have moved

In the 30 days to Sep 7, 2026, 36.5% of the 1933 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GRML was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.7M. The 52-week trading range was $4.37 to $38.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GRML - Latest Insights

GRML
Sep 04, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.81
Real-time Price: $4.74 info
Change: -$0.0671 (-1%) info
Market Cap: $15.123M info
GRML
Sep 03, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.87
Real-time Price: $4.74 info
Change: -$0.1295 (-3%) info
Market Cap: $15.123M info
GRML
Sep 02, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.97
Real-time Price: $4.74 info
Change: -$0.2295 (-5%) info
Market Cap: $15.123M info
GRML
Aug 28, 2026, 11:32 AM EDT
Source: FinanceWire
Importance Score:
8
Price at Filing: $5.16
Real-time Price: $4.74 info
Change: -$0.4145 (-8%) info
Market Cap: $15.123M info
GRML
Aug 27, 2026, 12:01 PM EDT
Source: FinanceWire
Importance Score:
7
Price at Filing: $4.95
Real-time Price: $4.74 info
Change: -$0.2045 (-4%) info
Market Cap: $15.123M info